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Abstract
A total of 256 men were studied to evaluate whether serum concentrations of perfluorooctanoate
(PFOA) and perfluorooctane sulfonate (PFOS) impacted semen quality or reproductive hormones.
Blood and semen were collected and analyzed for perfluorochemicals and reproductive and
thyroid hormones. Semen quality was assessed using standard clinical methods. Linear and
logistic modeling was performed with semen profile measurements as outcomes and PFOS and
PFOA in semen and plasma as explanatory variables. Adjusting for age, abstinence, and tobacco
use, there was no indication that PFOA or PFOS was significantly associated with volume, sperm
concentration, percent motility, swim-up motility and concentration, and directional motility (a
function of motility and modal progression.) Follicle stimulating hormone was not associated with
either PFOA or PFOS. Luteinizing hormone was positively correlated with plasma PFOA and
PFOS, but not semen PFOS. Important methodological concerns included the lack of multiple
hormonal measurements necessary to address circadian rhythms.
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1. INTRODUCTION
Perfluoroalkyls (PFAs) are carboxylates and sulfonates of various carbon-chain lengths that
have been found to be present in the environment as the result of direct and indirect sources
of exposure [1–3]. The most prevalent PFAs include perfluorooctanoate (PFOA), which is
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used as a processing aid in the manufacture of fluoropolymers, and perfluorooctane
sulfonate (PFOS), which is produced for the manufacture of surfactants, paper and
packaging treatments, and surface protectants. The widespread environmental presence of
PFOA and PFOS led a major manufacturer, 3M Company, to phase out production of its
perfluorooctanyl chemistry. Additional regulatory exposure-reduction control measures
from the U.S. Environmental Protection Agency have led the fluoropolymers industry to
work toward phasing out PFOA by 2015 [4]. Recent reports of declining concentrations of
PFOS and, to a lesser extent, PFOA in the general populations of the United States and
Norway suggest that some of these measures may have been effective [5–8].
In conjunction with the heightened awareness of PFOA and PFOS in the environment,
numerous toxicological and epidemiological research studies have been published, including
several investigations of developmental outcomes in rodents, as reviewed by Lau et al. [9].
Effects, including neonatal mortality and decreased pup weight gain, have been observed
with blood concentrations orders of magnitude higher than those measured in the general
human population [9, 10].
Recently, Joensen et al. [11] conducted a cross-sectional analysis of frozen (−20°C),
archived (5 years) serum samples collected from 105 Danish male military recruits at their
initial physical examination and measured the concentrations of nine PFAs, including PFOA
and PFOS, and several sex hormones. The researchers also evaluated semen parameters that
were originally measured at the date of examination. Upon summing the quartile category
scores for PFOS and PFOA into low, moderate, and high, Joensen et al. reported a
statistically significant difference in the median number of normal spermatozoa between the
low (15.5 million) and high (6.2 million) exposure groups, as well as in the percentage of
morphologically normal sperm (8.8 versus 6.3%). All PFOA and PFOS regression
coefficients were non-significantly negatively related with semen volume, sperm
concentration, count, motility, and morphology. Joensen et al. concluded that PFOS and
PFOA exposure may contribute to unexplained low semen quality observed in the general
population, but cautioned that their results were preliminary.
The consistent findings of developmental effects in animal studies in the absence of
toxicological evidence of reproductive effects attributable to PFOS and PFOA pertaining to
mating or semen quality [12–14] was the initial motivation for this study, especially in the
absence of non-occupational human data. The subsequent epidemiologic study published by
Joensen et al. that suggested an inverse association between PFOA and PFOS with male
semen quality heightened our interest in studying the biological effects PFOA and PFOS
exposures at environmental concentrations. This paper summarizes the findings from a study
of 256 men from the Durham, NC, area. These men presented with their partners to the
Duke Fertility Center (henceforth referred to as the In vitro Fertilization [IVF] Clinic) at
Duke University Medical Center for an assessment. Our study’s primary purpose was to
determine whether plasma and semen concentrations of PFOS and PFOA were associated
with semen quality and reproductive hormones.
2. METHODS
2.1 Study Design/Objectives
This was a cross-sectional study conducted between 2002 and 2005 in the Durham, NC, area
in collaboration with Duke University Medical Center’s IVF Clinic. If any exposure effects
are limited to a sensitive subset of the general population, this study population may be more
likely to reveal an association than a study that samples the general population. Samples of
blood and semen were collected and analyzed for PFOS and PFOA; concentrations in these
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biological matrices, especially blood, reflect multi-route exposures. These men were
anticipated to represent a range of general population exposures to these PFAs.
2.2 Sample and Data Collection
All data collection protocols and informed consent were approved by the Institutional
Review Boards at both RTI International (RTI) and Duke University Medical Center. Duke
University Medical Center’s IVF Clinic recruited a total of 256 men to participate in this
study between 2002 and 2005.
Blood and semen samples were collected at the time of evaluation and stored in
polypropylene containers prior to analyses. Aliquots of plasma and semen were placed into
polypropylene cryotubes, stored at −20°C, and transported to RTI for analysis of hormones,
PFOS, and PFOA. Reproductive health questionnaires were administered that inquired about
medical history and sexual activity, including duration of abstinence prior to sample
collection.
2.3 Sample Analysis
2.3.1 Semen Analysis—Both routine semen measures (e.g., viscosity, volume, pH,
sperm concentration, white blood cell concentration) and tests of functional motility (e.g., 30
minute swim-up test) were assessed in the College of American Pathologists accredited
andrology laboratory at Duke University. The 30-minute swim-up total motile count was
included in our analysis because it is used clinically at the IVF Clinic at Duke University
Medical Center to determine which infertile couples should consider using intracytoplasmic
sperm injection to assist with fertilization. An internal quality improvement exercise at the
IVF Clinic at Duke University Medical Center revealed that a 30-minute swim-up count of
less than 1 million sperm/mL, or less than 100,000 sperm/mL, correlated with a risk of poor
fertilization (i.e., less than 20% of oocytes) of 15% and 85%, respectively, following natural
insemination (Walmer, D., unpublished data).
Semen samples were obtained within 7 days of the last ejaculation, but after a minimum 48-
hour abstinence timeframe. Upon collection of the semen sample into a sterile specimen cup,
the sample was delivered to the laboratory within 1 hour. If an off-site sample was delivered
to the laboratory that was greater than 1 hour old and the motility of the spermatozoa was
less than 25%, then the patient was rescheduled. While en route to the laboratory, the
samples were not exposed to temperature extremes (not less than 25°C and not greater than
40°C). Motility assessment was performed using a Cell-Vu counting chamber within a 35–
37°C temperature range. The concentration of spermatozoa in the semen was determined by
using an improved Neubauer hemacytometer using the following serial dilutions: no
dilution, 1:10, and 1:100 in distilled water. Each parameter (motility and concentration) was
measured in duplicate, and the assessments must have been within 10% of each other.
Briefly, the swim-up assay was prepared by pipetting one-quarter of the semen volume into
two 15-mL centrifuge tubes for swim-up preparation. A total of 5 mL of insemination
medium was added to each tube and thoroughly mixed for 10 minutes. After centrifuging,
the supernatant was aspirated and discarded from both tubes. Two milliliters of insemination
media were then added to one of the tubes, and the pellet was resuspended. The suspension
was then transferred to the second tube, and the pellet was resuspended with subsequent
centrifuging at 200 × g for 10 minutes. The supernatant was discarded, and then 2.5 mL of
insemination medium were added to overlay the pellet. The tube was then incubated for 30
minutes at 37°C and 5% carbon dioxide in room air with subsequent careful transfer of the
top 1 mL of overlay to a clean 15-mL centrifuge tube for determination of concentration and
motility of the swim-up fraction. Forward linear progress was estimated as spermatozoon
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moving within 45 degrees to either side in the direction the head is pointing at a rate of at
least two head lengths per second.
2.3.2 Categorical Variables for Regression—Frequency distributions for the six
categorical semen profile measurements (i.e., liquefaction, viscosity, volume, sperm
concentration, modal progression, and swim-up overnight progression) analyzed as normal
or abnormal suggested that the males in this study were more typical of fertile males (Table
1). Dichotomous variables reflecting normal and abnormal were created from the continuous
measurements for three of these parameters (i.e., volume, sperm concentration, and swim-up
overnight motility) based on reference values in the World Health Organization’s
Laboratory Manual for the Examination and Processing of Human Semen [15] or IVF
laboratory practices as follows:
• Liquifaction:
– Normal: Liquified by 60 minutes at room temperature
– Abnormal: Not liquified by 60 minutes at room temperature
– “Liquefied” is defined as the ability to draw the sample into a pipette
• Viscosity:
– Normal: Pipetable
– Abnormal: Not pipetable
• Volume:
– Normal: ≥ 1.5 mL [15]
– Abnormal: <1.5 mL
• Sperm Concentration:
– Normal: ≥ 15 × 106/mL [15]
– Abnormal: <15 × 106/mL
• Modal Progression:
– Normal: >50% of the motile sperm made definite forward linear progress
– Abnormal: >50% of the motile sperm made weak or no forward progress
• Swim-Up Overnight Motility [15]:
– Normal: ≥28%
– Abnormal: <28%.
2.3.3 Hormone Analysis—Hormone analyses were conducted at RTI. Total and free
testosterone, follicle-stimulating hormone (FSH), luteinizing hormone (LH), prolactin,
triiodothyronine (T3), and thyroxine (T4) assay kits were purchased from Diagnostic
Products Corporation (now Siemens Healthcare Diagnostics, Deerfield, IL) and were
validated in human samples prior to use on the study samples. Estradiol and thyroid-
stimulating hormone (TSH) assay kits were purchased from Diagnostic Systems
Laboratories (now Beckman Coulter, Webster, TX).
2.3.4 Chemical Analysis—Representative samples of all supplies that would contact
blood, semen, or their extracts were screened for PFOS or PFOA by rinsing with methanol
and analyzing the extract by high-performance liquid chromatography with tandem mass
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spectrometry (HPLC-MS/MS) as subsequently described. Extracts containing PFOS or
PFOA above instrument background resulted in the rejection of those specific supply lots.
All perfluorinated standards were purchased from Sigma-Aldrich (St. Louis, MO). At the
time when the analytical method was set up, fully characterized, isotopically labeled
standards were not available to us, so the non-labeled homologs perfluorodecanoic acid
(PFDA) and perfluorododecanoic acid (PFDoA) were used as surrogate recovery and
quantitation standards, respectively. PFDA, as received, contained 0.6% of PFOA. At the
spiking concentration used (5 ng/mL in the sample), this would contribute to <5% of the
lower limit of quantification; nevertheless, the PFDA was further purified by preparative
HPLC (see Supplementary Information) to give a single peak (<0.1% of PFOA) by HPLC-
MS/MS. Semen samples were thawed, and 0.5 mL was transferred to a polypropylene tube;
5 μL of a PFDA solution (500 μg/mL) and 0.5 mL of a 1.4% phosphoric acid solution were
added, and the sample was vortexed. Solid-phase extraction columns (Oasis WAX, 6 cc,
Waters Corporation, Milford, MA) were preconditioned with 3 mL of methanol and then 3
mL of water. Samples were loaded, and columns were washed with 4 mL of 25 mM acetate
buffer, pH 5.0, followed by 4 mL of methanol. The columns were eluted with 4 mL of 20/80
methanol/acetonitrile (v/v) + 2% of ammonium hydroxide. The solvent was evaporated at
45°C under a stream of nitrogen, and the residue was reconstituted in 500 μL of methanol,
spiked with 50 μL of quantitation standard solution (PFDoA at 135 ng/mL), and transferred
to an autosampler vial. The same method was used to prepare the plasma samples, except
that 3-cc Oasis WAX columns were used, and column washing and eluent volumes were
accordingly reduced by half.
Extracts were analyzed on a PE-Sciex API-3000 HPLC-MS/MS Vernon Hills, IL) system
using negative electrospray ionization, with data acquired in the multiple reaction
monitoring mode. Separation was accomplished using a Betasil C18, 100 × 2.0-mm, 5-μm
particle LC column (Thermo Fisher Scientific, Waltham, MA) with the following gradient
program: mobile phase “A” = 5% methanol: 95%, 2 mM ammonium acetate in water;
mobile phase “B” = 95% methanol: 5%, 2 mM ammonium acetate in water. The mobile
phase was initially held at 50% B for 5 minutes, followed by a linear gradient to 100% B
over 20 minutes and returned to 50% B in 1 minute with a 10-minute hold for column re-
equilibration. Data were acquired using PE-Sciex Analyst 1.1 software under Microsoft
Windows NT 4.0. Calibration was carried out using solutions containing PFOS and PFOA
concentrations ranging from 0.1 to 100 ng/mL.
2.3.5 Quality Assurance/Quality Control
Quality Control: To characterize method performance and define the quality of the data,
field blanks, field controls, laboratory method blanks, and laboratory method control
samples were prepared and analyzed throughout the study, along with samples from study
participants. During instrumental analysis, a calibration check standard was analyzed every
10 samples to verify stability of the instrument calibration. Calibration was considered stable
if the deviation of the calculated check standard concentration was less than ±15% of
nominal. In addition, 16 samples of both semen and plasma were extracted and analyzed in
duplicate to characterize method precision. Duplicate samples were averaged for data
analysis. Instrumental analysis precision was characterized by analyzing a subset of sample
extracts in duplicate.
Quality Assurance: Analytical performance was further explored to demonstrate that our
method utilized from 2002 to 2005 yielded results comparable to those obtained using
current analytical methods employing istopically labeled internal standards. Therefore, an
interlaboratory comparison was performed whereby 30 plasma samples that had been
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analyzed at RTI prior to 2005 were transferred in 2008 to 3M Company’s Strategic
Toxicology Laboratory (St. Paul, MN) for independent determination of PFOS and PFOA
by HPLC-MS/MS using isotopically labeled internal standards. Concentration data from
each laboratory were compared by paired t-tests with cognizance of variance in
homogeneity.
2.4 Statistical Analysis
Data from questionnaires, semen profile measurements, and the chemical analyses of PFOS
and PFOA in semen and plasma were assembled into SAS (v.9.2) data sets and evaluated for
comparability between the original data and analysis-level data sets. Exact agreement was
confirmed for the number of measurements for PFOS, PFOA, semen profile characteristics,
and hormones in each matrix against the number of samples collected and analyzed.
Summary distributions for all measurements were examined for the presence of unusual
values; all extreme values were confirmed against the raw laboratory data. Lastly, accuracy
of data import into SAS was confirmed by confirmation of at least 10% of all measurements
against the original data.
Summary statistics for continuous variables (i.e., semen profile and perfluorooctyl
measurements) and categorical variables (i.e., questionnaire responses) were generated by
univariate and frequency analyses, respectively, on the complete data sets. Assessment of
distributional assumptions for the continuous outcome variables revealed no significant
difference in model fit for logged or unlogged outcomes; therefore, only unlogged outcomes
were modeled for both semen and plasma. Both logistic and linear modeling efforts were
performed using unlogged PFA explanatory variables in a three-phased approach:
1. A sub-model with PFOS and PFOA alone as explanatory variables, without
correction for age, duration of abstinence, or tobacco use (primarily smoking)
2. A full model with PFOS, PFOA, age duration of abstinence, and tobacco use
3. A forward selection model with PFOS and PFOA required admitting age, duration
of abstinence, and tobacco only when their significance in the model was within an
alpha of 0.5.
Odds ratios were computed for categorical outcomes by modeling against the most favorable
outcome (e.g., normal modal progression).
All measurements for two participants were excluded based on a white blood cell count of
17 × 105/mL for one participant and a duration of abstinence of 30 days for another. These
extreme values were not representative and accounted for less than 1% of our study





Duplicates: Replicate extraction and analysis of 21 pairs of plasma samples yielded
coefficients of variation (CVs) of 22% for PFOA and 16% for PFOS. Replicate analysis of
17 semen samples yielded a CV of 21% for PFOS; PFOA semen concentrations were too
low to yield useful precision data. Duplicate instrumental analysis yielded CVs of 3 to 18%
across analytes and matrices.
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Surrogate Recovery: Mean surrogate (PFDA) recoveries from plasma and semen quality
control samples and study samples are summarized in Table 2. In general, recovery of the
surrogate was consistent across matrices and sample types.
Controls: Recoveries from laboratory method controls are summarized in Table 3. Analyte
recoveries from three field plasma controls were 68 to 87% for PFOS, and 109 to 148% for
PFOA, consistent with ranges from method controls. Recoveries from five field semen
controls were 61 to 87% for PFOS, and 66 to 86% for PFOA, also consistent with the
method controls.
Blanks: Perfluorocarbon-based fittings and solvent transfer lines on the HPLC contributed
to a background PFOA signal that was kept at acceptable levels by system flushing. Before
analysis of any sample batch, a system blank was assessed to ensure that the background
contribution of PFOA was less than 20% of the lowest calibration standard. If the PFOA
background concentrations were found to be excessive, the system was flushed with 50 mL
of mobile phase, and the new blank was analyzed. Using PFOA measurements in laboratory
method blanks, we determined the detection limits (40 Code of Federal Regulations Part
136, Appendix B) to be 1.2 ng/mL for both semen (n = 44) and plasma (n = 27). The PFOS
background concentration was lower and blank analyses yielded detection limits of 0.4 ng/
mL for both semen and plasma. Field blanks (n = 5 for semen, n = 3 for plasma) were
consistent with method blanks.
3.1.2 Quality Assurance—A comparison of the 30 plasma samples that were analyzed
jointly by RTI and 3M Company, by examination of the measurement ratios, when values
were surrogate-corrected and uncorrected, yielded the best agreements using PFOS
uncorrected for surrogate recovery (Spearman ranked correlation of 0.752, p = <0.0001; see
Figure S1). For PFOA, the best measurement agreement was for PFOA corrected for
surrogate recovery (Spearman ranked correlation of 0.305 for uncorrected; Figure S2a and
0.712, (p <0.0001) for corrected, see Figure S2b). Paired t-tests (with correction for variance
heterogeneity) performed on the corrected and uncorrected RTI data versus 3M Company’s
results showed statistically significant (p <0.0001, p = 0.0119) differences between the two
measurements in all cases except the surrogate recovery-corrected PFOA results.
3.2 Analyses
Tables 4 through 6 provide measures of central tendency of matrix-dependent PFOS and
PFOA concentrations (ng/mL) and hormones as related to factors that may influence semen
quality (e.g., age, duration of abstinence, tobacco use) and the actual measurements. Of the
254 subjects whose median age and duration of abstinence was 41.0 years and 3.0 days,
respectively, their median sperm concentration was 58 × 106/mL (a range of 0 to 432 × 106/
mL), with the percent motile sperm observed at 53.3% (Table 4). Both swim-up
concentration and the swim-up total motile concentration (swim-up concentration × swim-
up motility) had median counts of 1.5 × 106 mL-1. Median plasma PFOS and PFOA
concentrations were 32.3 ng/mL and 5.2 ng/mL, respectively (Table 5). The median semen
PFOS concentration was 0.6 ng/mL. Only 2% of the semen PFOA concentrations were
reported greater than the limit of quantitation. All median hormone concentrations presented
in Table 6 were measured within their respective reference ranges (data not shown).
Differences in the number of observations are attributable to limitations in sample quantities
for semen PFA analyses, and to completeness of covariates required for modeling.
As expected, plasma PFOS and PFOA concentrations were highly correlated with each other
(ρ = 0.669, p <0.0001), as was PFOS plasma and semen concentrations (ρ = 0.441, p
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<0.0001). Plasma PFOA and semen PFOS concentrations were not significantly correlated
(ρ = 0.107, p = 0.113).
Provided in Table 7 are the unadjusted and adjusted regression PFOS (plasma and semen)
and PFOA (plasma) coefficients, 95% confidence intervals, and p values for 10 semen
quality characteristics. There were no statistically significant unadjusted or adjusted
coefficients, including those for the swim-up total motile count (swim-up count × motility
%) for PFOS in plasma (βadj= 0.0007, p = 0.850), PFOS semen (βadj = 0.0256, p = 0.861),
and plasma PFOA (βadj = 0.0085, p = 0.548). In addition, there were no statistically
significant odds ratios observed when five semen quality characteristics were categorized as
normal or abnormal (Table 8). Statistically significant correlations with hormones (p <0.05)
were observed (Table 9) for the following: (1) plasma PFOS and T3, and (2) plasma PFOA
with free testosterone and LH. Marginal non-significant correlations were observed with
plasma PFOS and LH, as well as plasma PFOA and T4. Estradiol, total testosterone, FSH,
and prolactin were not significantly correlated with PFOS plasma and semen concentrations
or with plasma PFOA.
4. DISCUSSION
Along with their female partners, a total of 256 males presented for fertility assessments at
Duke University Medical Center’s IVF Clinic. In our cross-sectional analysis of these data,
we did not observe semen quality to be statistically significantly (negatively) associated with
either plasma or semen concentrations of PFOS, or with plasma PFOA levels. Assessment of
semen quality was reasonably comprehensive and included the following: volume, sperm
concentration, percent motility, swim-up motility and concentration, and directional motility
(a function of motility and modal progression). We could not address semen quality related
to semen PFOA concentrations because less than 2% of these PFOA measurements were
above the limit of quantitation. In addition to semen quality analyses, several hormones
associated with spermatogenesis were measured. Among the most important hormone
indicators of impaired spermatogenesis, FSH was not associated with either PFOA or PFOS;
however, inhibin B was not measured [16]. LH was positively correlated with plasma PFOS
and PFOA, but not with semen PFOS. There were no statistically significant correlations
with total testosterone or estradiol. We have not quantitatively considered in our significance
threshold (p <0.05) comparisons of multiple hormone indicators with multiple chemical
measurements. This would result in a net reduction of the significance level by at least a
factor of nine; therefore, significance between p <0.01 and <0.05 must be viewed with
caution.
Statistically significant correlations were observed for TSH and plasma PFOS and T3 with
plasma and semen PFOS, but not plasma PFOA. In toxicological studies, the principal
diagnostic indicator of serum thyroid hormone status, TSH, was unchanged in animals
administered PFOS [12, 17–19]. Although, in these studies, there were reported decreases in
circulating levels of free thyroid hormones, these decreases were the result of an artificial
negative bias with the analog assay procedure employed. Such interference disappeared
when an equilibrium dialysis reference method was used [20]. This bias does not appear to
be a methodological issue with PFA measurements at the levels found in the blood of the
general population [21]. In addition, there were no changes in thyroid histology; hence, there
was no evidence of clinical hypothyroidism in experimental animal studies following either
short-term or long-term administration of PFOS [22]. General population and occupational
studies have occasionally shown various statistical associations with either thyroid
hormones, with PFOS [23, 24], or with PFOA [25], but none of them have represented
clinically relevant changes.
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The distributions of the PFOA and PFOS concentrations measured in our study were
comparable to the time-related (2003–2004) collection data reported by the Centers for
Disease Control and Prevention for the general U.S. population [5] and slightly higher than
those reported by Joensen et al. [11] in their study of sperm quality in Danish military
recruits. This difference could be attributed to geography and the declines in PFOS and, to a
lesser extent, PFOA in the U.S. general population [5].
Both Joensen et al.’s [11] research and our study could not address temporality because of
their cross-sectional designs and because they lacked the multiple hormonal measurements
necessary to address hormonal circadian rhythms. Both studies measured serum PFOS and
PFOA concentrations similar to those observed in the general population [5, 6].
Nevertheless, the two studies reported different associations regarding semen quality.
Joensen et al. observed a 60% (p < 0.03) decline in median normal spermatozoa between
their study subjects defined as having high versus low combined serum PFOS and PFOA
concentrations. There was essentially no indication that PFOS or PFOA was associated with
any semen quality parameter in our study. We cannot offer any substantive reasons for the
different findings in semen quality between the two studies, despite similar general
population-level PFOS and PFOA concentrations. The one substantive difference is the
older age of our study population. No studies published in the literature have assessed semen
quality of highly exposed workers involved in the manufacture of PFAs. Occupational
epidemiologic studies [26–28] have shown inconsistent associations between serum
concentrations of PFOA (measured to be two to three orders of magnitude higher than the
general population) and estradiol and testosterone. Measurements of FSH and LH were not
associated with PFOA in the only occupational setting that reported this analysis [27].
There are two studies that examined male reproductive toxicity data in rats exposed to PFOS
or PFOA [12–14]. Luebker et al. [12] conducted a two-generation reproduction study of
PFOS in CD® rats. Male rats were administered (by gavage) 0.0, 0.1, 0.4, 1.6, and 3.2 mg/
kg-day of potassium PFOS beginning 42 days prior to mating and through the mating
period. Although no specific semen parameters were reported, mating and fertility
parameters were not adversely affected for any dose group. Fertility indices (i.e., the number
of pregnancies per the number of rats that mated) for male rats were 94.3, 91.4, 81.8, 85.0,
and 87.5% for the control and four dose groups, respectively. Fertility indices for female rats
were 94.3, 91.4, 82.4, 85.3, and 85.7%, respectively. All females were successfully mated
except for one rat in the 0.4 mg/kg-day group.
In a two-generation reproduction study of PFOA administered to rats at 0, 1, 3, 10, and 30
mg/kg-day, Butenhoff et al. [13] reported that there was normal fertility and sperm
parameters, without providing specifics. Detailed analyses were subsequently provided by
York et al. [14] who reported cauda epididymal sperm motility, count, and density, and
spermatid count and density in both the P- and F1-generation male rats across these dose
groups. No statistically significant trends were observed except for static count in the P-
generation male rats. Based on historic control data of the laboratory, this trend was
attributed to a higher static count in the control rats rather than the lower comparable counts
in the four dosed groups. No significant trends in abnormal morphology were reported in
either the P- or F1-generation male rats.
In another study, Biegel et al. [29] reported an increase in estradiol levels from PFOA–
treated rats. This increase was primarily due to aromatase induction in the liver. Data from a
sub-chronic rodent study also suggested the same outcome [30]. Estradiol and testosterone
measurements were measured in male and female monkeys administered (by gavage) doses
of potassium PFOS at 0, 0.03, 0.15, and 0.75 mg/kg-day [17]. Lowered estradiol values were
reported in both male and female monkeys in the 0.75 mg/kg-day dose group. This outcome
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was not observed for testosterone. As previously discussed, estradiol levels were not
significantly associated with increased PFOA concentrations in our study.
A potential limitation in the measurements in our study was the unavailability of isotopically
labeled standards for the analysis of plasma and semen samples for PFOS and PFOA. In
additional to an interlaboratory study in which the RTI method for the determination of PFA
compounds in plasma was found to perform comparably to techniques used by other
laboratories [31], method suitability was assessed by the analysis of a subset of 30 samples
from the current study at 3M Company’s laboratory Although the plasma measurements
made at the two laboratories are similar, only RTI’s recovery-corrected PFOA results
compare quantitatively to the results obtained for this analyte at 3M Company’s laboratory.
The improvement in agreement and correlation of RTI’s data with 3M Company’s data on
application of a surrogate recovery, as illustrated in Figure S2a and b, are consistent with the
expected behavior during sample preparation associated with chemically similar PFDA
(surrogate) and PFOA. Carboxylic and sulfonic acids may be reasonably expected to behave
more dissimilarly during sample preparation, and it is not surprising that correction of RTI’s
PFOS data using PFDA recoveries did not improve agreement with 3M Company’s data.
That the paired t-tests for the uncorrected PFOS concentrations indicated a difference
between the two laboratories is a function of the high correlation between most of the
sample values; if a single outlier evident at the top left of Figure S1 is excluded from both
analyses, the bias in both data sets is identical. Our conclusion regarding the comparison
between the two laboratories is that although different results were found, because different
methodologies were used, the highly significant correlations between RTI’s and 3M
Company’s measurements for a given chemical species, even for surrogate-unadjusted
values, strongly suggests that these differences do not materially affect the results of this
study.
5. CONCLUSIONS
Our study participants were selected because they were presumed to represent both fertile
and infertile populations. If PFOA or PFOS adversely affected spermatogenesis, our
working hypothesis was that the association may be more readily detected in an infertile
male population. Of the 256 men evaluated at Duke University Medical Center’s IVF Clinic
as part of an assessment of infertility among couples, PFOS and PFOA were measureable in
90% of the plasma and 59% and 2%, respectively, of the semen samples, with a median
value of PFOS in serum four to five times higher than that for PFOA. Plasma concentrations
were similar to those reported in time-dependent general population studies. Concentrations
in semen were nearly an order of magnitude lower than those measured in plasma. Plasma
PFOS was highly correlated with semen PFOS concentrations, but this could not be
determined for PFOA, owing to the few semen measurements exceeding the instrumental
detection limit.
There was no indication that PFOS or PFOA were significantly associated with any semen
quality parameter. Assessment of semen quality included the following: volume, sperm
concentration, percent motility, swim-up motility and concentration, and directional motility
(a function of motility and modal progression). Among the most important hormone
indicators of impaired spermatogenesis, FSH was not associated with either PFOA or PFOS,
and LH was positively correlated with plasma PFOS and PFOA, but not with semen PFOS.
Because of our study’s cross-sectional design, important methodological issues pertaining to
hormonal analyses could not be addressed, including the need for multiple measurements to
adequately address circadian variations in hormone concentrations.
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